The EVICEL® Neurosurgery Phase III Study

January 8, 2019 updated by: Ethicon, Inc.

A Single-Blinded, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® Fibrin Sealant (Human) Compared to a Hydrogel Sealant as an Adjunct to Sutured Dural Repair

The objective of this study is to evaluate the safety and efficacy of EVICEL® Fibrin Sealant (Human) for use as an adjunct to sutured dural repair in cranial surgery.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
234

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Sydney, New South Wales, Australia, 2109
        • Clinical Investigation Site #51
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Clinical Investigation Site #54
    • Victoria
      • Melbourne, Victoria, Australia
        • Clinical Investigation Site #50
      • Richmond, Victoria, Australia, 3121
        • Clinical Investigation Site #52
  • Belgium
      • Genk, Belgium
        • Clinical Investigation Site #40
      • Leuven, Belgium
        • Clinical Investigation Site #41
  • Canada
    • Quebec
      • Montreal, Quebec, Canada, H3A 2B4
        • Clinical Investigation Site #25
  • New Zealand
      • Auckland, New Zealand, 1023
        • Clinical Investigation Site #53
  • United Kingdom
    • England
      • London, England, United Kingdom
        • Clinical Investigation Site #35
      • Middlesborough, England, United Kingdom
        • Clinical Investigation Site #32
      • Nottingham, England, United Kingdom
        • Clinical Investigation Site #35
      • Oxford, England, United Kingdom
        • Clinical Investigation Site #30
      • Salford, England, United Kingdom
        • Clinical Investigation Site #31
  • United States
    • California
      • Los Angeles, California, United States, 90033
        • Clinical Investigation Site #27
      • Sacramento, California, United States, 95817
        • Clinical Investigation Site #17
    • Florida
      • Jacksonville, Florida, United States, 32207
        • Clinical Investigation Site #18
      • Tampa, Florida, United States, 33606
        • Clinical Investigation Site #19
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Clinical Investigation Site #22
    • Louisiana
      • New Orleans, Louisiana, United States, 70121
        • Clinical Investigation Site #10
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • Clinical Investigation Site #15
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Clinical Investigation Site #11
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Clinical Investigation Site #24
    • New Jersey
      • New Brunswick, New Jersey, United States, 08903
        • Clinical Investigation Site #20
    • New York
      • New York, New York, United States, 10065
        • Clinical Investigation Site #12
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • Clinical Investigation Site #14
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Clinical Investigation Site #21

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subjects ≥18 years of age undergoing craniotomy/craniectomy for pathological processes in the supratentorial region or posterior fossa
  • Subjects or legally authorized representatives must be willing to participate in the study and provide written informed consent.
  • Surgical wound classification Class I
  • The cuff of native dura along the craniotomy edge on each side is adequate, based on surgeon's judgment, to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product
  • Presence of intra-operative cerebrospinal fluid (CSF) leakage following primary dural closure or after Valsalva maneuver

Exclusion Criteria:

  • Subjects with a dural lesion from a recent surgery that still has the potential for CSF leakage.
  • Chemotherapy within 30-days prior to enrollment or scheduled within 7-days following surgery
  • Radiation therapy to the head within 30-days prior to enrollment or scheduled within 7-days following surgery
  • A previous craniotomy/craniectomy within 6 months prior to the study surgery.
  • Known hypersensitivity to the components of the investigational product.
  • Subjects with a known allergy to FD&C Blue #1 dye
  • Subjects with an infection present at the surgical site
  • Subjects with an infection indicated by any one of the following: clinical diagnosis of infection, fever, positive urine culture, positive blood culture, positive chest X-ray.
  • Female subjects of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period.
  • Female subjects who are nursing.
  • Exposure to another investigational drug or device clinical trial within 30 days prior to enrollment or anticipated in the 60 day follow-up period.
  • Subjects with severely altered renal or hepatic function, with a compromised immune system or autoimmune disease who can NOT receive hydrogel sealant.
  • Subjects with penetratring traumatic injuries to the head with damage to the dura
  • Dural injury during craniotomy/craniectomy that cannot be eliminated by widening the craniotomy/craniectomy to recreate the native dural cuff.
  • Patient has a gap between durotomy edges of greater than 2mm after primary dural closure.
  • Approaches that would not allow sutured dural closure such as trans-sphenoidal or trans-labirinthine-/petrosal/-mastoid. Superficial penetration of mastoid air cells are allowed.
  • Use of implants made of synthetic materials coming into direct contact with dura
  • Use of other fibrin sealants or PEG-based sealants on the dural closure. Approved fibrin sealants may be used for hemostasis if not in contact with the dura.
  • Hydrocephalus, except occlusive hydrocephalus caused by posterior fossa pathology or incompletely open cerebrospinal fluid pathways, to be treated during surgical procedure.
  • Placement of Gliadel Wafers
  • Intersecting durotomy scars in the surgical path from a previous operation that cannot be completely removed by the planned dural resection.
  • Two or more separate cranial dural defects, including defects from ventricular cannulation and ventriculo-peritoneal shunting.
  • Subjects with any other intra-operative findings identified by the surgeon that may preclude the conduct of the study procedure.
  • Confined bony structures where nerves are present where neural compression may result due to swelling.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: EVICEL Fibrin Sealant
EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
Biological: EVICEL Fibrin Sealant
Other Names:
  • fibrin sealant
Active Comparator: Hydrogel sealant
The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
Device: Hydrogel sealant

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Primary Effectiveness Endpoint Success Number of Successes (Subjects That Had no Inter-operative CSF Leak Following Valsalva Maneuver and no CSF Leak or Pseudomeningocele in the Surgical Area During the 30-day Follow-up Period)
Time Frame: Intraoperatively through 30-day follow-up
The primary endpoint was the proportion of subjects that had no inter-operative CSF leak following Valsalva maneuver and no CSF leak or pseudomeningocele in the surgical area during the 30-day follow-up period
Intraoperatively through 30-day follow-up

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Safety Endpoint: Intra-operative CSF Leakage Follow Final Valsalva
Time Frame: Intraoperatively, after final Valsalva maneuver
Intra-operative CSF leakage follow final Valsalva
Intraoperatively, after final Valsalva maneuver

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ethicon, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2015

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 13, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 12, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 27, 2015

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 27, 2015

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 29, 2015

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 10, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 8, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BIOS-14-002
  • 2014-003954-15 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings